Transcriptional regulation of FoxO3 gene by glucocorticoids in murine myotubes. by Kuo, Taiyi et al.
UC Berkeley
UC Berkeley Previously Published Works
Title
Transcriptional regulation of FoxO3 gene by glucocorticoids in murine myotubes.
Permalink
https://escholarship.org/uc/item/4rr5r5vq
Journal
American journal of physiology. Endocrinology and metabolism, 310(7)
ISSN
0193-1849
Authors
Kuo, Taiyi
Liu, Patty H
Chen, Tzu-Chieh
et al.
Publication Date
2016-04-01
DOI
10.1152/ajpendo.00214.2015
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
doi: 10.1152/ajpendo.00214.2015
310:E572-E585, 2016. First published 12 January 2016;Am J Physiol Endocrinol Metab 
Cassandra Lei, Andy Chau, Yicheng Tang, Edna Cheung and Jen-Chywan Wang
Taiyi Kuo, Patty H. Liu, Tzu-Chieh Chen, Rebecca A. Lee, Jenny New, Danyun Zhang,
glucocorticoids in murine myotubes
Transcriptional regulation of FoxO3 gene by
You might find this additional info useful...
 52 articles, 26 of which you can access for free at: This article cites
http://ajpendo.physiology.org/content/310/7/E572.full#ref-list-1
 including high resolution figures, can be found at: Updated information and services
http://ajpendo.physiology.org/content/310/7/E572.full
 can be found at: Metabolism
American Journal of Physiology - Endocrinology and about Additional material and information
http://www.the-aps.org/publications/ajpendo
This information is current as of August 5, 2016. 
Physiological Society. ESSN: 1522-1555. Visit our website at http://www.the-aps.org/. 
American Physiological Society, 9650 Rockville Pike, Bethesda MD 20814-3991. Copyright © 2016 the American
endocrine and metabolic systems on any level of organization. It is published 24 times a year (twice monthly) by the 
 publishes results of original studies aboutAmerican Journal of Physiology - Endocrinology and Metabolism
 by guest on August 5, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
 by guest on August 5, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
Transcriptional regulation of FoxO3 gene by glucocorticoids
in murine myotubes
Taiyi Kuo,1,2 Patty H. Liu,2 Tzu-Chieh Chen,2 Rebecca A. Lee,1,2 Jenny New,2 Danyun Zhang,2
Cassandra Lei,2 Andy Chau,2 Yicheng Tang,2 Edna Cheung,2 and X Jen-Chywan Wang1,2
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Kuo T, Liu PH, Chen TC, Lee RA, New J, Zhang D, Lei C,
Chau A, Tang Y, Cheung E, Wang JC. Transcriptional regula-
tion of FoxO3 gene by glucocorticoids in murine myotubes. Am J
Physiol Endocrinol Metab 310: E572–E585, 2016. First published
January 12, 2016; doi:10.1152/ajpendo.00214.2015.—Glucocorti-
coids and FoxO3 exert similar metabolic effects in skeletal muscle.
FoxO3 gene expression was increased by dexamethasone (Dex), a syn-
thetic glucocorticoid, both in vitro and in vivo. In C2C12 myotubes the
increased expression is due to, at least in part, the elevated rate of FoxO3
gene transcription. In the mouse FoxO3 gene, we identified three gluco-
corticoid receptor (GR) binding regions (GBRs): one being upstream of
the transcription start site, 17kbGBR; and two in introns, 45kbGBR
and 71kbGBR. Together, these three GBRs contain four 15-bp gluco-
corticoid response elements (GREs). Micrococcal nuclease (MNase)
assay revealed that Dex treatment increased the sensitivity to MNase in
the GRE of 45kbGBR and 71kbGBR upon 30- and 60-min Dex
treatment, respectively. Conversely, Dex treatment did not affect the
chromatin structure near the17kbGBR, in which the GRE is located in
the linker region. Dex treatment also increased histone H3 and/or H4
acetylation in genomic regions near all three GBRs. Moreover, using
chromatin conformation capture (3C) assay, we showed that Dex treat-
ment increased the interaction between the17kbGBR and two genomic
regions: one located around 500 bp and the other around 73 kb.
Finally, the transcriptional coregulator p300 was recruited to all three
GBRs upon Dex treatment. The reduction of p300 expression de-
creased FoxO3 gene expression and Dex-stimulated interaction
between distinct genomic regions of FoxO3 gene identified by 3C.
Overall, our results demonstrate that glucocorticoids activated
FoxO3 gene transcription through multiple GREs by chromatin
structural change and DNA looping.
glucocorticoids; glucocorticoid receptor; FoxO3; myotube; chromatin
structure; gene transcription
GLUCOCORTICOIDS PLAY A CRITICAL role in the regulation of
skeletal muscle physiology. Glucocorticoids inhibit glucose
utilization and protein synthesis while promoting protein deg-
radation in skeletal muscle. Inhibiting glucose utilization pre-
serves plasma glucose, the primary energy source for brain.
Promotion of protein degradation and repression of protein
synthesis produce free amino acids, which can be used as the
substrates for hepatic gluconeogenesis. These effects are im-
portant metabolic adaptations for the survival of mammals
during stress conditions, such as fasting and starvation. How-
ever, chronic or excess glucocorticoid treatment can cause
severe metabolic disorders, such as muscle atrophy and insulin
resistance in skeletal muscle (21, 32, 35, 39, 40).
Glucocorticoids exert their biological functions mainly
through binding to an intracellular receptor, the glucocorticoid
receptor (GR). Upon binding to glucocorticoids, GR is re-
cruited to genomic glucocorticoid response elements (GRE) to
regulate the transcription of its target genes. These primary
target genes then trigger glucocorticoid-regulated physiologi-
cal responses. Our previous chromatin immunoprecipitation
sequencing (ChIPseq) experiments identified four GR binding
regions (GBR) in or near the mouse FoxO3 gene (22). The
induction of FoxO3 mRNA and protein levels by glucocorti-
coids has been shown previously both in vitro and in vivo (15,
29, 34, 50, 52). The FoxO3 gene encodes a transcription factor
that plays a vital role in skeletal muscle protein and glucose
metabolism (9, 33). First, the transcription factor inhibits
glucose oxidation by activating the transcription of pyruvate
dehydrogenase kinase 4 (PDK4) (23). Interestingly, glucocor-
ticoids also induce PDK4 gene transcription (23). In the human
PDK4 gene promoter, the binding of both FoxO3 and FoxO1,
another member of the FoxO transcription factor family, is
necessary for the maximum level of glucocorticoid-induced
PDK4 transcription (23). Second, like glucocorticoids, the
FoxO3 transcription factor stimulates the transcription of genes
that activate protein degradation, such as MuRF1 and
atrogin-1, and genes that suppress protein synthesis, such as
Eif4ebp1 (37, 47). MuRF1 and atrogin-1 are muscle-specific
ubiquitin ligases that have been shown to mediate muscle
atrophy caused by various conditions. Constitutively active
FoxO3 has been shown to be sufficient to induce muscle
atrophy, whereas dominant negative FoxO3 has been shown to
prevent the muscle atrophy caused by either disuse or gluco-
corticoids (37, 47). Furthermore, the dominant negative form
of FoxO3 suppresses glucocorticoid-induced atrogin-1 gene
expression (37, 47). Recently, microRNA that decreases
FoxO3 gene expression has been shown to decrease glucocor-
ticoid-induced expression of atrogin-1 gene in C2C12 myo-
tubes (15). Overall, these results strongly suggest that gluco-
corticoid-regulated glucose and protein metabolism requires
the participation of FoxO3.
Because of the important role of FoxO3 in glucocorticoid
action, we systematically examined the mechanisms of gluco-
corticoid-regulated FoxO3 gene expression in this report. With
nuclear run-on assay, we examined whether the FoxO3 gene
was transcriptionally regulated by glucocorticoids. We charac-
terized the four GBRs in the FoxO3 gene identified by ChIPseq
and further identified 15-bp GREs that mediate the glucocor-
ticoid response within these GBRs. The acetylation status of
histone H3 and H4 surrounding these GBRs was checked.
Moreover, we mapped the position of nucleosomes wrapped by
these GBRs and studied the effect of glucocorticoid treatment
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on their chromatin structures. Finally, we used chromatin
conformation capture (3C) assay to test the potential interac-
tions between GBRs and the genomic region near the transcrip-
tion start site (TSS).
EXPERIMENTAL PROCEDURES
Cell culture. Mouse C2C12 cells were purchased from the Cell and
Tissue Culture Facility at the University of California Berkeley. They
were maintained in Dulbecco’s modified Eagle’s medium (DMEM;
Mediatech) containing 10% fetal bovine serum (FBS; Tissue Culture
Biologicals) and incubated at 37°C with 5% CO2. Upon reaching
95100% confluence, C2C12 myoblasts were differentiated into
myotubes with 2% horse serum (J. R. Scientific) in DMEM. The
C2C12 cells were maintained in 2% horse serum-containing DMEM,
changed every 2 days, until fully differentiated into myotubes, in
4–6 days. For cell culture experiments, C2C12 myotubes were
treated with various concentrations of Dex (Sigma), RU486 (Mifepri-
stone; Sigma), or an equal volume (0.05% vol/vol of media) of vehicle
control ethanol (EtOH) or DMSO.
Animals. Male 8-wk-old C57BL/6 mice were purchased from
Charles River. Mice were injected with 5 mg/kg Dex (Sigma) or PBS
for 1 or 4 days. After the treatment, gastrocnemius muscles were
isolated from mice for gene expression analysis. For in vivo ChIP,
male 8-wk-old C57BL/6 mice were injected with PBS or Dex at 11
AM for 2 or 3 h. Gastrocnemius muscles were then isolated for ChIP.
Gastrocnemius muscle of 14-wk-old transgenic mice overexpressing
corticotropin-releasing hormone (CRH) (46) and wild-type (WT)
C57BL/6 mice were provided by the laboratory of Charles Harris
(Washington University, St. Louis, MO). In these CRH-Tg transgenic
mice, the CRH gene was driven by mouse metallothioneine-1 pro-
moter. Thus the CRH gene was overexpressed in almost all tissues in
these transgenic mice. The levels of corticosterone were 10 times
higher than normal C57BL/6 mice (46). The Office of Laboratory
Animal Care at the University of California Berkeley (Approval No.
R306-0111) approved all animal experiments conducted in this study.
Nuclear run-on. C2C12 myotubes were untreated or treated with 1
M Dex for 30 min and 1, 2, or 4 h. Cells were then washed once with
PBS, and 3 ml of lysis buffer (10 mM Tris·HCl pH 7.4, 3 mM MgCl2,
10 mM NaCl, 150 mM sucrose, and 0.5% NP40) were added to each
plate, followed by incubation at 4°C for 10–15 min. Cell lysate was
collected and spun at 170 g at 4°C for 5 min to pellet the nuclei.
Nuclei were washed once with lysis buffer without NP40 and resus-
pended in freezing buffer (50 mM Tris·HCl at pH 8.3, 40% glycerol,
5 mM MgCl2, and 0.1 mM EDTA). The total number of nuclei from
each of the untreated and Dex-treated samples was counted, and 1 
106 nuclei were used for in vitro transcription. Two aliquots from each
sample were used: one sample was incubated in 100 l of 2 in vitro
transcription buffer [200 mM KCl, 20 mM Tris·HCl pH 8.0, 5 mM
MgCl2, and 4 mM dithiothreitol (DTT); 4 mM each of ATP, GTP and
CTP; 200 mM sucrose; and 20% glycerol] with 8 l biotin-UTP
(Roche, or equal amount from Epicentre), and the other sample was
incubated in 100 l 2 in vitro transcription buffer with 8 l UTP
(negative control) for 60 min at 30°C. Then, 6 l of 250 mM CaCl2
and 6 l of RNAse-free DNase (10 U/ml; Roche) were added to stop
the reactions. Total RNA was isolated using the Nucleospin RNA II
kit (Macherey-Nagel).
Dyna beads M-280 (Invitrogen) were washed twice in solution A
(0.1 mM NaOH and 0.5 M NaCl) for 5 min, once in solution B (0.1
M NaCl) for 5 min, and then resuspended in binding/wash buffer (10
mM Tris·HCl pH 7.5, 1 mM EDTA, and 2 M NaCl) with 1 l (40
units) RNasin per 100 l of beads. Then, 50 l of beads were added
to total RNA isolated, incubated at 42°C for 30 min, followed by
vigorous shaking on a shaker at room temperature for 3 h. The beads
were precipitated with magnets and centrifugation, and the superna-
tant was discarded. The beads were then washed once for 15 min with
500 l 15% formamide with 2 saline-sodium citrate (SSC) buffer,
twice for 5 min with 1 ml 2 SSC buffer, and then resuspended in 30
l RNase- and DNase-free water. Finally, 10 l of beads were used
for each reverse transcription (RT) reaction before real-time PCR
(qPCR). These primers were used in qPCR: mFOXO3_runon_F,
ACTCCCGTCTTTTCCTCTCC; mFOXO3_runon_R, GGAAGT-
GATCTTGGCAGGTC; mRPL19_cDNA_F, ATGGAGCACATC-
CACAAGC; and mRPL19_cDNA_R, TCCTTGGTCTTAGACC-
TGCG.
RNA isolation and quantitative PCR. Total RNA was isolated from
mouse gastrocnemius muscles using TRI Reagent RT (Molecular
Research Center). To synthesize randomly primed cDNA, 0.5 g of
total RNA, 4 l of 2.5 mM dNTP, and 2 l of 15 M random primers
(New England Biolabs) were mixed at a volume of 16 l and
incubated at 70°C for 10 min. Then, a 4-l cocktail containing 25
units of Moloney murine leukemia virus (M-MuLV) Reverse Tran-
scriptase (New England Biolabs), 10 units of RNasin (Promega), and
2 l of 10  reaction buffer (New England Biolabs) was added, and
samples were incubated at 42°C for 1 h and then at 95°C for 5 min.
The cDNA was diluted and used to perform real-time quantitative
PCR (qPCR) using the EVA QPCR SuperMix Kit (Biochain), fol-
lowing manufacturer’s protocol. qPCR was performed in either a
7900HT, 7500HT, or StepOne PCR System (Applied Biosystems) and
analyzed with the -Ct method, as supplied by the manufacturer
(Applied Biosystems). Rpl19 gene expression was used for internal
normalization. Primer sequences for qPCR were as follows:
Rpl19_cDNA_F, ATGGAGCACATCCACAAGC, Rpl19_cDNA_R,
TCCTTGGTCTTAGACCTGCG; FoxO3_cDNA_forward, TTCAA-
CAGTACCGTGTTTGGAC; and FoxO3_cDNA_reverse, AGTGT-
GACACGGAAGAGAAGGT.
Western blotting. RIPA buffer (10 mM Tris·HCl pH 8.0, 1 mM
EDTA, 150 mM NaCl, 5% glycerol, 0.1% sodium deoxycholate, 0.1%
SDS, and 1% Triton X-100), supplemented with protease inhibitors,
was added to cell pellet. The mixture was gently rocked at 4°C for 1
h. The supernatant was then collected as protein sample. NuPAGE
Novex Bis-Tris mini gels (Invitrogen) were used, following the
manufacturer’s protocol, and proteins were transferred to nitrocellu-
lose membranes (Amersham) using semidry transfer (Bio-Rad) over-
night. The next day, membranes were blocked for 4 h at room
temperature with 10% (wt/vol) nonfat milk in TBS (50 mM Tris-base
and 200 mM NaCl pH 7.5). Membranes were then incubated in 5%
milk in TBS with appropriate primary antibody with gentle rocking
overnight at 4°C. The following day, membranes were washed with
TBS plus 0.5% Tween-20 at pH 7.5 (TBST), and then incubated in 5%
milk in TBS containing appropriate secondary antibody for at least 2
h at room temperature. The membranes were then washed with TBST,
and proteins were detected by chemiluminescence (Western Lighting
Plus-ECL; Perkin Elmer). For additional protein detection on the same
membrane, membranes were soaked in TBS overnight at 4°C, and
stripped for 30 min in PBS with 7 l/ml -mercaptoethanol, followed
by 30 min in PBS only, and 4 h in 10% milk in TBS before reprobing
with other primary antibodies. The following antibodies were used:
FoxO3 (07–702; Millipore), p300 (sc-584; Santa Cruz Biotechnol-
ogy), -actin (C4) mouse monoclonal IgG1 (sc-47778; Santa Cruz
Biotechnology), GAPDH (ab9483; abcam), anti-rabbit IgG1-HRP
(Cell Signaling), and anti-goat IgG-HRP (sc-2768; Santa Cruz Bio-
technology). Blots were scanned and analyzed with ImageJ software
(http://rsbweb.nih.gov/ij). -Actin or GAPDH was used as an internal
control.
Plasmids, transfection, and luciferase reporter assay. pGL4.10-
E4TATA reporter plasmid was generated by insertion of a 50-bp
minimal E4 TATA promoter sequence (25) into the Bgl II to Hind III
sites of vector pGL4.10 to drive luciferase expression (1). Each
chosen GBR fragment, extending 100–150 bp upstream and down-
stream of the GBR, was amplified from genomic C2C12 DNA (primer
sequences are available in Supplemental Material S1; Supplemental
Material for this article is available online at the Journal website),
using the Expand Long Template PCR System (Roche Applied
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Science) and cloned into the pGL4.10-E4TATA vector with Kpn
I/Xho I sites. We also replaced E4 TATA promoter region with the
promoter region of FoxO3 gene (70 to 25 bp relative to its
transcription start site, TSS). The QuikChange Lightning mutagenesis
kit (Stratagene) was used to make site-directed mutations per the
manufacturer’s instructions. Lipofectamine 2000 (Invitrogen) was
used to transfect C2C12 myoblast according to the technical manual.
Twenty-four hours posttransfection, cells were treated with either 1
M Dex or control EtOH in differentiation media for 16–20 h. Cells
were then harvested and their luciferase activities were measured with
the Dual-Luciferase Reporter Assay kit (Promega) according to pro-
cedures in the technical manual.
Chromatin immunoprecipitation. Fully differentiated C2C12 myo-
tubes were treated with 1 M Dex or control EtOH for 1 h and cross
linked in 2% formaldehyde for 3 min at 37°C. The reactions were
quenched with 0.125 M glycine. The cells were then washed with 1
PBS, scraped, and lysed in cell lysis buffer (50 mM HEPES-KOH at
pH 7.4, 1 mM EDTA, 150 mM NaCl, 10% glycerol, and 0.5% Triton
X-100), supplemented with protease inhibitor cocktails (Calbiochem).
The cell lysate was incubated for 1 h at 4°C, and the crude nuclear
extract was collected by centrifugation at 600 g for 5 min at 4°C. The
nuclei were resuspended in 1 ml of ice-cold RIPA buffer (10 mM
Tris·HCl at pH 8.0, 1 mM EDTA, 150 mM NaCl, 5% glycerol, 1%
Triton X-100, 0.1% sodium deoxycholate, and 0.1% SDS, supple-
mented with protease inhibitor). The chromatin was fragmented with
a Branson Sonifier 250 sonicator (13 min total, 20-s pulse at 35%
power followed by 40-s pause). To remove insoluble components, we
centrifuged the samples at 13,000 rpm for 15 min at 4°C and
recovered the supernatant. Fifty microliters of lysates were retained
and prepared as input. After proteinase K treatment and reverse cross
linking, DNA fragments were purified using QIAquick PCR purifi-
cation kit (Qiagen) as described at the end of this paragraph. For GR
ChIP, 1 g of rabbit polyclonal anti-GR antibody (N499, provided by
Keith R. Yamamoto laboratory, University of California, San Fran-
cisco) was added to the supernatant to immunoprecipitate GR-bound
chromatin at 4°C overnight. For histone modification ChIP, the
following antibodies were used: anti-histone H3 (ab1791; abcam),
anti-acetyl histone H3 (ab47915; abcam), anti-histone H4 (05–858;
Millipore), anti-acetyl histone H4 (06–866; Millipore), CBP (sc-
7300x; Santa Cruz Biotechnology), and p300 (sc-584x; Santa Cruz
Biotechnology). Normal rabbit IgG antibody (sc-2027; Santa Cruz
Biotechnology) was used as negative control for all ChIP. The next
day, 100 l of 50% protein A/G (GR ChIP; Santa Cruz Biotechnol-
ogy) or protein A (histone modification ChIP; Upstate) bead slurry,
containing 100 g/ml salmon sperm DNA, were added into each
immunoprecipitation and nutated at 4°C for 2 h. The beads were then
washed twice with RIPA buffer, three times with RIPA buffer con-
taining 500 mM NaCl, twice with LiCl buffer (20 mM Tris at pH 8.0,
1 mM EDTA, 250 mM LiCl, 0.5% NP-40, and 0.5% sodiumdeoxy-
cholate), and one time with RIPA buffer, all supplemented with
protease inhibitor. After the remaining wash buffer was removed, 75
l of proteinase K solution (TE pH 8.0, 0.7% SDS, and 200 g/ml
proteinase K) was added to each immunoprecipitation reaction,
followed by incubation at 55°C for 3 h and 65°C overnight to
reverse formaldehyde cross linking. ChIP DNA fragments were
purified with QIAquick PCR purification kit (Qiagen), eluting in 60
l of Qiagen Elution Buffer. Primers used for ChIP are in Sup-
plemental Material S1.
For each ChIP experiment, the percentage of input was calculated
by taking the ratio of ChIP DNA fragment to input DNA fragment.
Since input DNA fragments were isolated from 50 l whereas ChIP
DNA fragments were purified from 950 l lysate, the 19 difference
was taking into consideration for data calculation.
In vivo ChIP. The in vivo ChIP protocol was modified from two
previous reports (41, 42). Mice were injected intraperitoneally with
Dex (5 mg/kg body wt, in 200 l solution) or an equal volume of PBS.
Gastrocnemius muscles were excised and snap frozen in isopentane
cooled by liquid nitrogen and then crushed into a fine powder using a
mortar and pestle. Samples were suspended in a 1% formaldehyde
solution in PBS and incubated at 37°C for 10 min and incubated for
5 min in 125 mM of glycine. Samples were then re-suspended in 50
mM Tris pH 8, 1% SDS, 10 mM EDTA, 1 mM DTT, and protease
inhibitors and then incubated at 10°C for 10 min and sonicated at 60%
output for a total of 50 s. Cleared lysates were then diluted threefold
in a dilution buffer of 0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris pH 8, 167 mM NaCl, and protease inhibitor.
One-hundred microliters of 50% protein A/G beads with 5 g of IgG
antibody were added and incubated for 1 h at 4°C. Supernatants were
collected and samples were incubated with antibodies overnight at
4°C. Beads were washed once with a low-salt washing buffer (150
mM NaCl, 20 mM Tris pH 8.1, 0.1% SDS, 1% Triton X-100, and 2
mM EDTA), a high-salt washing buffer (500 mM NaCl, 20 mM Tris
pH 8.1, 0.1% SDS, 1% Triton X-100, and 2 mM EDTA), a LiCl
washing buffer (250 mM LiCl, 1% sodium deoxycholate, 1% Nonidet
P-40, 1 mM EDTA, and 10 mM Tris pH 8.1), and twice with
Tris-EDTA buffer. Protein-chromatin complexes were eluted with 10
mM DTT, 1% SDS, and 100 mM NaHCO3 for 1 h, and the superna-
tant was then incubated overnight at 65°C with 200 mM NaCl.
Proteins were digested with Proteinase K for 3 h at 55°C and DNA
fragments were isolated using QIAquick DNA purification kit (Qia-
gen, Valencia, CA). Real-time PCR were used to monitor the recruit-
ment of GR to various GBRs.
MNase assay. The protocol for MNase assay was previously
described (43). Briefly, C2C12 myotubes were treated with 1 M Dex
or an equal volume (0.05% vol/vol of media) of vehicle control
ethanol (EtOH) for 30 or 60 min. Cells were cross linked with 1%
formaldehyde for 3 min at 37°C, and the reaction was quenched by the
addition of glycine to a final concentration of 0.125 M. Cells were
then washed once with PBS and scraped in ice-cold MNase NP-40
lysis buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5%
NP-40, 0.15 mM spermine, and 0.5 mM spermidine). After being
shaken for 3–5 h at 4°C in MNase lysis buffer, nuclei were collected
by centrifugation and washed in ice-cold MNase digestion buffer
without CaCl2 (10 mM Tris at pH 7.4, 15 mM NaCl, 60 mM KCl, 0.15
mM spermine, and 0.5 mM spermidine). Samples were then resus-
pended in ice-cold MNase digestion buffer with CaCl2 (10 mM Tris
at pH 7.4, 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM
spermidine, and 1 mM CaCl2). Nuclei were treated with 1 unit of
MNase (nuclease micrococcal from Staphylococcus aureus; N5386-
200UN; Sigma-Aldrich) for 60–90 min at 25°C. Reactions were
stopped by the addition of 80 l MNase digestion buffer with CaCl2,
20 l MNase stop buffer (100 mM EDTA and 10 mM EGTA), 75 g
proteinase K, and 20 l 10% SDS, and then cells were incubated at
65°C overnight. Samples were run on 1.5% agarose gel, and single
nucleosome-wrapped DNA (150 bp) was purified with Qiagen gel
extraction kit. The concentration of the samples was measured and
diluted to 0.3 ng/l for use in qPCR. The qPCR primers were
designed to span 500-bp regions, covering the identified GREs in
each of the GBRs. When there were gaps between primers, the gaps
were no more than 20 bp long. Primers used for MNase assay are
available in Supplemental Material S1. Notably, a titration curve
using genomic DNA was performed for each primer in individual
MNase experiment to calculate for the absolute DNA amount.
Lentiviral infection. Mouse C2C12 myoblasts were infected with
p300 shRNA lentiviral particle (sc-29432v; Santa Cruz Biotechnol-
ogy) or control shRNA lentiviral particle (sc-108080; Santa Cruz
Biotechnology) and selected with 5 g/ml puromycin for several
days. Sh-p300 and sh-scr C2C12 myoblasts were then differentiated
into myotubes. Three days after differentiation, 1 M Dex or EtOH
was added to sh-p300 or sh-scr myotubes for 6 h, followed by Western
blotting or gene expression assay.
Chromatin conformation capture. Two 15-cm plates of C2C12
myotubes were used: one treated with 1 M Dex, the other with
control EtOH for 1 h. After treatment, cells were fixed in 2%
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formaldehyde and incubated at 37°C for 3 min. Glycine was added to
a final concentration of 0.125 M at room temperature for 5 min to
quench the cross linking. Cells were then washed with ice-cold PBS
and resuspended in 5 ml of ice-cold PBS. The cells were transferred
through a 40-m nylon cell strainer (BD Falcon 352340) and centri-
fuged at 320 g (100 rpm) at 4°C for 7 min. The pellet was then
resuspended in 20 ml ice-cold lysis buffer (10 mM Tris·HCl at pH 8.0,
10 mM NaCl, 0.2% NP-40, and complete protease inhibitor) and
rotated at 4°C for at least 1 h. Samples were centrifuged at 15,000 to
18,000 rpm at room temperature for 5 min and resuspended in 2 ml of
1.1  Bgl II restriction enzyme buffer, 60 l of 10% SDS (final
concentration 0.3%), and 200 l of 20% Triton X-100 (final concen-
tration 1.8%) and shaken at 37°C for 1 h. Then, 1,600 units of Bgl II
restriction enzyme were added to each sample and incubated at 37°C
overnight. The next day, 320 l of 10% SDS (final concentration
1.3%) were added and incubated at 65°C for 30 min, followed by the
addition of 1.5 ml of 20% Triton X-100 (final concentration 1%), 2.8
ml of 10 T4 DNA ligase buffer (NEB), and up to 28 ml of deionized
water, followed by incubation at 37°C for 1 h. Then, 1 l of T4 DNA
ligase (400 units) was added to each sample, and samples were kept
at 4°C overnight. The next day, 60 l of proteinase K (20 mg/ml;
Fermentas) were added, and samples were incubated at 65°C over-
night. The next morning, 120 l of RNase A (10 mg/ml; Fermentas)
were added, followed by a 45-min incubation at 37°C. Four rounds of
phenol/chloroform extraction were used to clear SDS, and the aqueous
phase was recovered. Then, DNA was precipitated with 0.1 vol of 3
M sodium acetate at pH 4.8 and 2 vol of 100% ethanol in 80°C
overnight, followed by centrifugation at 4,000 rpm at 4°C for 60 min.
The DNA pellets were washed with 70% ethanol and spun at 4,000
rpm at 4°C for 10 min. The DNA pellets were dissolved in 500 l of
TE buffer, pH 8.0. Forward and reverse primers for qPCR are
designed to flank the junction of Bgl II restriction enzyme site and
were paired (see Fig. 6). Primers for 3C are listed in Supplemental
Material S1.
Statistical analysis. Error bars are means 	 SE for each group.
Student’s t-test was used for all statistical analyses.
RESULTS
Glucocorticoids increase the expression of FoxO3 gene in
vitro and in vivo. C2C12 myotubes were treated with vehicle
control EtOH or Dex (1 M), a synthetic glucocorticoid, for 2,
6, 24, or 48 h. Except for the 2-h treatment, Dex markedly
increased FoxO3 gene expression at all time points (Fig. 1A).
We then used the shortest yet effective treatment time (6 h) for
the subsequent dose-response analysis. As shown in Fig. 1B,
while treatment of 10 and 100 nM of Dex significantly stim-
ulated the FoxO3 gene expression, 1 M of Dex provided the
strongest induction. By treating C2C12 myotubes with a com-
bination of Dex and RU486, a GR antagonist, we found that
RU486 cotreatment dose dependently reduced Dex-induced
FoxO3 gene expression (Fig. 1C). These results demonstrated
that Dex response on FoxO3 gene expression in C2C12 myo-
tubes is GR dependent.
To study the glucocorticoid effect on FoxO3 gene expres-
sion in vivo, WT mice were injected with control PBS or Dex
(5 mg·kg1·day body wt1) for 4 days. FoxO3 gene expression
was 2.5-fold higher in the gastrocnemius muscle from Dex-
injected WT mice than that from PBS-treated ones (Fig. 1D).
Next, we utilized transgenic mice overexpressing CRH (4, 14)
to examine long-term glucocorticoid effects on FoxO3 gene
expression. These transgenic mice have chronically elevated
levels of CRH, which stimulates the secretion of adrenocorti-
cotropin hormone (ACTH). ACTH further increases the secre-
tion of corticosterone to circulation. We found that FoxO3
gene expression was 1.8-fold higher in gastrocnemius mus-
cle from CRH-Tg mice than that from WT ones (Fig. 1E).
Overall, these experiments demonstrated that the expression of
FoxO3 was induced by glucocorticoids both in vitro and in
vivo.
To confirm that Dex-upregulated FoxO3 mRNA levels were
correlated with FoxO3 protein levels, C2C12 myotubes were
treated with Dex or control EtOH for 24 h. Immunoblotting
revealed that Dex treatment resulted in 1.5-fold increase of
FoxO3 protein levels (Fig. 1F).
Next, we performed nuclear run-on assay to test the induc-
tion of FoxO3 gene in transcriptional level by glucocorticoids.
Since transcriptional activation of the FoxO3 gene by Dex
should occur before the observation of its mRNA increase, we
chose time points earlier than 6 h for the nuclear run-on assay.
Figure 1G shows that FoxO3 transcription was significantly
induced by 0.5, 1, 2, and 4 h of the treatment. These results
indicate that the increased FoxO3 gene expression was due to,
at least in part, the induction of its transcription, as early as 0.5
h after Dex treatment.
Insulin antagonizes the effects of glucocorticoids on protein
metabolism, as it activates protein synthesis and reduces pro-
tein degradation (21, 40). To investigate whether insulin re-
presses glucocorticoid-induced FoxO3 gene expression,
C2C12 myotubes were treated with control EtOH, Dex, insu-
lin, or a combination of Dex and insulin for 6 h. As shown in
Fig. 1H, insulin reduces the basal expression of FoxO3 gene.
The absolute level of FoxO3 induction by Dex is also de-
creased by insulin; however, the fold change of Dex-induced
FoxO3 gene expression in the presence of insulin is similar to
that in the absence of insulin (3.2- vs. 3.2-fold, represented as
hash tags in Fig. 1H). These results suggest that insulin reduces
the expression of basal expression of FoxO3 gene rather than
suppressing Dex-stimulated FoxO3 gene transcription.
Identification of GBRs in the genomic region of FoxO3
gene. Previously, our ChIPseq identified four potential GBRs
in or near FoxO3 genomic region (22). These include the
genomic region between 17,455 to 17,126 (relative to the
TSS, referred to as the 17kbGBR), between 45,231 and
45,317 (called the 45kbGBR), between 71,380 and
71,565 (called the 71kbGBR), and between 98,640
and 98,777 (called the 93kbGBR). The 45kbGBR and
the 71kbGBR were located in introns, whereas the 93kb-
GBR was located in the 3=-untranslated region. Using conven-
tional ChIP we found that GR was recruited to the17kbGBR,
the 45kbGBR, and the 71kbGBR, but not the 93kbGBR,
upon 1-h treatment of Dex on C2C12 myotubes (Fig. 2A). We
individually inserted each GBR upstream of the TATA box in
a luciferase reporter, pGL4.10-E4TATA, and performed re-
porter assay. For C2C12 myoblasts transfected with reporters
containing the 17kbGBR, the 45kbGBR or the 71kb-
GBR, Dex-treated cells gave a significantly higher luciferase
activity than EtOH-treated ones (Fig. 2, C, E, and G). These
results indicate that the 17kbGBR, the 45kbGBR, and the
71kbGBR contain functional GREs that confer glucocorti-
coid responses.
We also replaced the promoter region of pGL-17kbWT,
pGL45kbWT, and pGL71kbWT with 70 to 25 (rela-
tive to TSS) region of FoxO3 gene. With FoxO3 promoter, all
three GBRs again conferred Dex response, although the levels
of response were lower (Fig. 2H).
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Next, we searched for sequences resembling the consensus
GRE identified from our ChIPseq (51), RGXACAnnnT-
GTXCY, in the 17kbGBR, the 45kbGBR, and the 71kb-
GBR. Based on the consensus sequences, nucleotide positions
2, 4, 5, 6, 10, 11, 12, and 14 have to be a specific nucleotide.
We looked for sequences that contain at least six of these eight
nucleotides. We mutated position 11 of this consensus GRE
from a G to a C residue, or position 5, from C to G (Fig. 2, B,
D, and F). These residues have been previously shown to make
direct contact with the GR (28). In the 17kbGBR, two
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Fig. 1. Induction of FoxO3 gene and protein expression by glucocorticoids in vitro and in vivo. A: C2C12 myotubes were treated with 1 M dexamethasone
(Dex) or control ethanol (EtOH) for 2, 6, 24, or 48 h; n 
 6. B: C2C12 myotubes were treated with 10 nM, 100 nM, 1 M, and 5 M Dex or control EtOH
for 6 h; n 
 6. C: C2C12 myotubes were treated with 50 nM Dex and with DMSO (vehicle control) or 25 nM, 50 nM, 100 nM, and 1 M of RU486 for 6 h;
n 
 5. D: male C57BL/6 mice were injected with 5 mg·kg1·day1 of Dex or control PBS for 1 day (24 h) or 4 days (96 h). Their gastrocnemius muscles were
isolated; n 
 10. E: gastrocnemius muscles were collected from wild-type and corticotropin-releasing hormone (CRH)-Tg mice; n 
 12. In A, B, C, and D,
primers specific to the FoxO3 and the Rpl19 (internal control) genes were used in quantitative (q)PCR for gene expressions analysis. Fold induction was
calculated by normalizing to Rpl19 and taking the ratio of Dex over EtOH. F: C2C12 myotubes were treated with 1 M Dex or control EtOH for 24 h, and FoxO3
protein levels were measured; n 
 3. G: nuclear run-on assay for monitoring FoxO3 in in vitro transcription. C2C12 myotubes were untreated or treated with
1 M Dex for 0, 0.5, 1, 2, or 4 h. Primers specific to FoxO3 (across exon 1 and intron 1) and Rpl19 (internal control) were used in qPCR; n 
 4. H: FoxO3
gene expression after cotreatment of Dex and insulin; n 
 3. C2C12 myotubes were treated with control EtOH, Dex, insulin (100 nM), or a combination of Dex
and insulin for 6 h. Fold induction is calculated by comparing treatment to EtOH. For all, error bars indicate means 	 SE. *P  0.05. #3.2-fold induction.
*(rep)Statistical significant repression compared with EtOH. **Statistically significant difference in fold induction between 100 nM and 1 M Dex treatment in
B, and among PBS, 50 nM Dex, and 1 M RU486 treatment in C.
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GRE-like sequences (GLSs) were found (Fig. 2B). Mutation of
GLS1 resulted in more than a 95% decrease in response to
Dex, whereas mutation of GLS2 caused about 80% reduction
of Dex response. Double mutation of GLS1 and 2 completely
abolished its response to Dex (Fig. 2C). These results sug-
gested that both GLS1 and 2 are required to confer glucocor-
ticoid response for 17kbGBR, while GLS1 plays a more
prominent role. In this regard, the sequence of GLS1, but not
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Fig. 2. The identification of glucocorticoid response
elements (GREs) in FoxO3 glucocorticoid receptor
(GR) binding regions (GBRs). A: chromatin immu-
noprecipitation (ChIP) to confirm GR recruitment
to GBRs identified from ChIP (ChIPseq). C2C12
myotubes were treated with 1 M Dex or control
EtOH for 1 h. Primers flanking the17kbGBR, the
45kbGBR, the 71kbGBR, the 93kbGBR, and
Rpl19 (negative control) were used in qPCR. Error
bars represent the means 	 SE of the fold enrich-
ment from 3 independent experiments. *P  0.05.
B: 17kbGBR genomic region. C: reporter assay
for plasmid containing 17kbGBR. D: 45kb-
GBR genomic region. E: reporter assay for plasmid
containing 45kbGBR. F: 71kbGBR genomic
region. G: reporter assay for plasmid containing
71kbGBR. For B, D, and F, the location of each
GBR, the sequence of consensus GRE, the se-
quence of GRE-like sequences (GLSs), and each
mutated nucleotide are shown. For C, E, and G,
reporter plasmids described in B, D, and F were
cotransfected with a human GR expression vector
and a Renilla internal control plasmid in C2C12
myoblasts, and their luciferase activities are shown.
The t-test is calculated by comparing each reporter
plasmid to pGL4.10 E4TATA vector. H: FoxO3
neutral promoter region 70 to 25 bp, relative to
its transcription start site, was cloned into pGL4.10
reporter plasmid to give pGL4.10 FoxO3 promoter
reporter; n  5. Fold induction was calculated by
taking the ratio of luciferase activity in Dex-treated
samples over EtOH-treated ones. Error bars repre-
sent means 	 SE. *P  0.001. I and J: ChIP to
confirm GR recruitment to GBRs in gastrocnemius
muscle after 2 h (I) and 3 h (J) PBS or Dex
treatment. Error bars represent the means 	 SE of
the fold enrichment from at least 3 independent
experiments. *P  0.05.
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the sequence of GLS2, is highly conserved in human and rat
FoxO3 gene (Table 1).
For the 45kbGBR, three GLSs were located (Fig. 2D).
Mutation of GLS2 had no effect on Dex response, whereas
mutation of GLS3 gave a 57% decrease in response to Dex
(Fig. 2E). Furthermore, mutation of GLS1 completely elimi-
nated its response to Dex (Fig. 2E). These results indicated that
GLS1 plays a primary role and GLS3 plays an accessory role
in mediating glucocorticoid response. Notably, the GLS1 se-
quence is also highly conserved in human and rat FoxO3 genes
(Table 1).
For the 71kbGBR, four GLSs were found (Fig. 2F).
Mutation of GLS2, 3, or 4 had no effect on the Dex response
(Fig. 2G). However, mutation in GLS1 completely removed its
response to Dex (Fig. 2G). Therefore, GLS1 alone conferred a
complete glucocorticoid response in the 71kbGBR, and its
sequence is also conserved in human and rat FoxO3 genes
(Table 1).
To test whether three GBRs identified from C2C12 myo-
tubes are occupied by GR in vivo, mice were injected with PBS
or Dex at 11 AM. Two or three hours postinjection their
gastrocnemius muscles were isolated for ChIP. We found that
GR occupied 45kbGBR and 71kbGBR in gastrocnemius
muscle after 2- and 3-h PBS treatment (Fig. 2, I and J,
respectively). This suggests that endogenous corticosterone
was enough to induce GR recruitment to these two GBRs.
Treating mice with Dex for 2 and 3 h further enhanced GR
recruitment on these two GBRs in gastrocnemius muscle (Fig.
2, I and J). On the contrary, GR was recruited to 17kbGBR
after 2 h PBS treatment (Fig. 2, I and J), but the recruitment
was not enhanced by Dex. Overall, these results confirmed that
GR is recruited to the three GBRs in vivo.
Glucocorticoids increase the level of acetylated histones in
FoxO3 genomic region surrounding GBRs. Histone hyper-
acetylation is highly associated with transcription activation.
We monitored the levels of acetylated histone H3 and H4
(AcH3 and AcH4, respectively) as well as total H3 and H4 in
FoxO3 genomic regions containing GRE and regions located
upstream and downstream from each GRE. For the 17kb-
GBR, the 45kbGBR, and the 71kbGBR, there is no signif-
icant change in the total H3 and H4 levels between control
EtOH and Dex treatment (Fig. 3, A–C). All three genomic
regions present significant levels of acetylated H3 and H4
before Dex treatment (Fig. 3, D–F). These observations sug-
gest that those are likely regulatory regions that play a role in
controlling basal FoxO3 gene expression. Dex treatment mark-
edly induced hyperacetylation of H3 or H4 in genomic regions
surrounding all three GREs (Fig. 3, D–F), although the status
of histone acetylation was not affected on the GRE region of
each GBR. The ratio of acetylated histones vs. total histones
was calculated to more precisely reflect histone hyperacetyla-
tion status. Dex treatment increased AcH4/H4 levels upstream
of the45kbGBR (Fig. 3H), as well as downstream of all three
GBRs (Fig. 3, G–I). Dex treatment also elevated AcH3/H3
level downstream of the17kbGBR (Fig. 3, G). Overall, these
results indicate that glucocorticoids increase the acetylation
status of histones surrounding, but not within, each GRE.
Glucocorticoid treatment differentially induce chromatin
structural changes in GBRs. Treatment of glucocorticoids has
been shown to disrupt nucleosome assembly or change the
position of nucleosomes in the genome. We used MNase to
map the position of nucleosomes surrounding the three FoxO3
GBRs.
For the 17kbGBR, three nucleosomes were detected:
17,550 to 17,400, 17,400 to 17,250, and 17,200 to
17,050. Dex treatment did not affect the position of these
three nucleosomes, as their sensitivity to MNase was similar
between EtOH-treated and Dex-treated cells. Interestingly, the
major GRE (17,231 to 17,217) in the 17kbGBR is
located in a linker region between nucleosome 2 and 3 (Fig. 4,
A and B).
For the 45kbGBR, two nucleosomes were observed:
44,850 to 45,050 and 45,250 to 45,450. These nucleo-
somes appeared to cover more than 146 bp of DNA, probably
due to the lack of overlapping primer sets in certain GC-rich
regions. Nonetheless, the effect of glucocorticoids on these
nucleosomes is apparent. Dex treatment for 30 min markedly
increased the sensitivity to MNase of both nucleosomes (Fig.
4C). This increase of sensitivity, however, was not seen in cells
treated with Dex for 60 min (Fig. 4D). Thus the density of
chromatin structure of these two nucleosomes in the 45kb-
GBR region was reduced upon 30-min Dex treatment, and it
was transient.
For the 71kbGBR region, three nucleosomes were de-
tected: 71,300 to 71,420, 71,420 to 71,560, and
71,560 to 71,700. Dex treatment for 30 min did not
significantly affect the position or sensitivity to MNase of these
nucleosomes (Fig. 4E). However, 60-min treatment signifi-
Table 1. Conservation of GRE in FoxO3 GBR
Type Location Sequence n
Mouse 17KbGBR GLS1 (17,231 to 17,217) (chr 10, 42013789–42013775) AGGTCTTTCTGTTCC [6/8]
Human (16,519 to 16,533) (chr 6, 108971185–108971199) AGGTCTTTCTGTTCC [6/8]
Rat (12,290 to 12,276) (chr 20, 46275109–46275095) AGGGCATTCAGTTCC [6/8]
Mouse 45kbGBR GLS1 (45,266 to 45,252) (chr 10, 41951297–41951283) GTTACATCCTGGACT [6/8]
Human (61,314 to 61,328) (chr 6, 109049034–109049048) GGCACATTCTGTACT [8/8]
Rat (44,026 to 44,012) (chr 20, 46218771–46218757) GGTACGTCCTGTACT [7/8]
Mouse 71kbGBR GLS1 (71,492 to 71,478) (chr 10, 41925071–41925057) GGAATGGAATGTTCC [6/8]
Human (94,403 to 94,417) (chr 6, 109082123–109082137) GGAATGGAATGTTCT [6/8]
Rat (70,364 to 70,350) (chr 20, 46192453–46192439) GGAATGGAATGTTCC [6/8]
Genomic location of mouse glucocorticoid response element (GRE) and its conserved counterparts in human and rat genome are shown. Based on the
consensus GRE sequence identified from chromatin immunoprecipitation sequencing (ChIPseq), RGXACANNNTGTXCY, we looked for sequences that have
at least 6 identical nucleotides of 8 underlined nucleotides. The number of identical nucleotide (underlined) is shown in brackets. Mouse sequences are based
on mm9 assembly, human sequences are based on hg18 assembly, and rat sequences are based on Baylor 3.4/rn4 assembly. GBR, glucocorticoid receptor binding
region.
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cantly increased the sensitivity to MNase of the second nucleo-
some. In fact, this nucleosome is unrecognizable in the 60-min
Dex-treated sample (Fig. 4F). This result strongly suggests that
chromatin structure was loosened up in the region of 71,420
to 71,560. Interestingly, this region harbors the highly con-
served 71kb GLS1 sequence.
Overall, these results show that glucocorticoids differen-
tially modulate the chromatin structure of the three GBRs in
the FoxO3 genomic region, suggesting that distinct mecha-
nisms are adapted by these GBRs to participate in GR-acti-
vated FoxO3 gene transcription.
Dex-induced FoxO3 gene transcription requires p300. One
key hallmark for active GREs is the recruitment of transcrip-
tional coactivators by GR. We examined the recruitment of
transcriptional coregulators, p300 and CBP, to FoxO3 GBRs
upon 30-min Dex treatment. We found that p300, but not CBP,
was recruited to all three GBRs upon Dex treatment (Fig. 5A).
Reducing p300 in C2C12 myotubes with shRNA lentiviruses
(Fig. 5B) markedly decreased the induction of FoxO3 gene and
protein expression by Dex (Fig. 5, C and D). These results
indicated that p300 directly participates in GR-activated
FoxO3 gene transcription.
The potential interactions between genomic regions near
FoxO3 GBRs and 578 bp downstream of TSS. All three FoxO3
GBRs are located far away from the TSS. Therefore, to
stimulate FoxO3 transcription, they may need to interact with
the genomic region near the TSS, where the basal transcription
machinery is located. We performed 3C to examine the poten-
tial interaction between GBRs and TSS genomic regions.
C2C12 myotubes were treated with control EtOH or Dex for 30
or 60 min, cross linked, followed by nuclei isolation. The
samples were digested with restriction enzyme Bgl II and then
diluted for intracellular religation. With primers pairing be-
tween genomic regions near each GBR and TSS, qPCR was
used to assess the change in relative cross-linking frequencies
between Dex- and EtOH-treated samples. We tested more than
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FoxO3 genomic region of 17,308 to 17,184; the 17kbGBR 5= primer, 17,678 to 17,570; and the 17kbGBR 3= primer, 16,909 to 16,786. For B,
E, and H, the 45kbGBR primer defines FoxO3 genomic region of 45,219 to 45,302; the 45kbGBR 5= primer, 44,853 to 44,929; and the 45kbGBR
3= primer, 45,631 to 45,683. For C, F, and I, the 71kbGBR primer identifies FoxO3 genomic region of 71,443 to 71,555; the 71kbGBR 5= primer,
71,290 to 71,381; and the 71kbGBR 3= primer, 72,129 to 72,215. Error bars are means 	 SE; n  6 and * P  0.05.
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a 100 primer pairs, where most of them did not detect any PCR
products. Nevertheless, we found 14 primer pairs that detected
significant levels of PCR products. Figure 6A showed the
location of these primers (the nucleotide number represent the
midpoint of each primer sequence) in the FoxO3 genomic
region. Levels of these 14 ligated products were not affected by
30-min Dex treatment (data not shown). However, upon 60-
min Dex treatment, the levels of two ligated products were
significantly increased (Fig. 6, B and C): between primer pair
73,506 and 17,648 (2.3-fold induction, primer 7) and
primer pair17,648 and578 (2.3-fold induction, primer 14).
This finding suggests that Dex treatment enhanced DNA loop-
ing in a time-dependent manner, and resulted in increased
interaction between the 3= end of the 71kbGBR and the
17kbGBR, and between the 17kbGBR and the genomic
region 578 bp downstream of TSS.
To test whether p300 is involved in Dex-induced DNA
looping, we performed 3C in EtOH- or Dex-treated C2C12
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Fig. 4. Nucleosome mapping of the FoxO3
GBRs. C2C12 myotubes were treated 1 M
Dex or control EtOH. Nucleosome positions
were analyzed with MNase digestion, fol-
lowed by qPCR with primers spanning
FoxO3 GBRs. For A and B, nucleosome
mappings between 17,600 and 17,100 of
the FoxO3 gene are shown for 30-min and
1-h treatment, respectively. Eleven primers
were used to span this region. For C and D,
nucleosome mappings between44,800 and
45,600 of the FoxO3 gene are shown for
30-min and 1-h treatment, respectively. Nine
primers were used to span this region. For E
and F, nucleosome mappings between
71,300 and 71,700 of the FoxO3 gene
are shown for 30 min and 1 h, respectively.
Nine primers were used to span this region.
For Fig. 4, the positions of nucleosomes are
drawn. Error bars represent means 	 SE of
the genomic DNA amount from at least 5
independent experiments. *P  0.05, for the
indicated primer comparing Dex to EtOH-
treated samples.
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myotubes that express scramble shRNA (control) or p300
shRNA. Consistent with the results above, Dex treatment
resulted in 1.8-fold induction between primer pair 73,506
and 17,648, and 1.6-fold induction between primer pair
17,648 and 578 in C2C12 myotubes that express scramble
shRNA (Fig. 6D). In contrast, both inductions were abolished
with the presence of p300 shRNA (Fig. 6D). These results
indicate that p300 is required for Dex-induced interaction
between these genomic elements in FoxO3 gene.
DISCUSSION
Glucocorticoids and FoxO3 play similar roles in the regula-
tion of protein and glucose metabolism in skeletal muscle. The
induction of FoxO3 gene expression by glucocorticoids could
have important physiological and/or pathological implications.
Here, we extensively studied the mechanism of glucocorticoid-
activated FoxO3 gene expression. We showed that glucocorti-
coids activated the transcription of the FoxO3 gene in C2C12
myotubes. We identified three GBRs in or near the FoxO3 gene
and the functional GREs within the GBRs. Interestingly, these
three GBRs are far away from FoxO3 TSS. Several lines of
evidence suggest that they all play a role in glucocorticoid-
activated FoxO3 gene transcription.
First, all three GBRs confer glucocorticoid response when
individually inserted into a reporter plasmid. Among these
GBRs, four functional GREs were identified from nine GRE-
like sequences. Intriguingly, the sequences of three out of the
four GREs (one from each GBR) are highly conserved in
human and rat FoxO3 gene (Table 1), suggesting that these
GREs in human and rat may also play a role in glucocorticoid-
regulated FoxO3 gene transcription. Alternatively, these GREs
are conserved due to selective pressure in evolution. Previous
studies have shown that certain glucocorticoid-regulated genes,
such as tyrosine aminotransferase and dual specificity phos-
phatase 1, contain multiple GREs (7, 48). Moreover, ChIP
sequencing results revealed many glucocorticoid-regulated
genes contain multiple GR binding regions in their genome (8,
22, 36, 51), which suggests that regulation of gene transcrip-
tion by multiple GREs is likely a common mechanism.
We also showed that GR was recruited to these GBRs in
vivo. GR was recruited to 45kb and 71kbGBR in gastroc-
nemius muscle of PBS-treated mice, which indicates a basal
level of GR occupancy at these GBRs. Notably, Dex further
enhanced GR recruitment to both 45kb and 71kbGBR. In
contrast, GR occupancy on 17kbGBR was not enriched with
Dex treatment, which suggests that further GR recruitment to
17kbGBR likely required other signals or transcription fac-
tors.
Second, we observed changes in chromatin structure sur-
rounding two GBRs: 45kbGBR and 71kbGBR. An in-
crease in sensitivity to MNase was observed in the nucleosome
that contains the GRE in the 45kbGBR upon 30-min gluco-
corticoid treatment. However, there is no significant change in
chromatin structure of the 71kbGBR at the same time point.
Instead, the chromatin structure was disrupted upon 60-min
glucocorticoid treatment. Furthermore, upon 30-min glucocor-
ticoid treatment, while histone H4 was hyperacetylated both
immediately upstream and downstream of the 45kbGBR and
downstream of 17kbGBR and 71kbGBR, H3 was hyper-
acetylated upstream and downstream of 17kbGBR and up-
stream of 45kbGBR.
The chromatin structure surrounding the 17kbGBR was
not affected at either time point. Interestingly, its GRE is
located within the linker region between two nucleosomes.
Thus, unlike the GREs in the45kbGBR and the71kbGBR,
which are located within nucleosome, the GRE in the 17kb-
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Fig. 5. Acetyltransferase p300 is recruited to
all 3 FoxO3 GBRs and is involved in Dex
induced FoxO3 transcription. A: C2C12 myo-
tubes were treated with 1 M Dex or EtOH
for 30 min. ChIP was performed with anti-
bodies recognizing IgG (control), CBP, p300,
or GR, followed by qPCR with primers span-
ning FoxO3 GBRs. Fold enrichment was cal-
culated by taking the ratio Dex-treated sam-
ples over EtOH-treated ones. Dashed line
indicates EtOH-treated basal level of 1; n 

3. B: Western blotting shows that p300 is
knocked down in C2C12 myotubes treated
with shRNA lentiviral particle against p300
compared with that against control scramble
(scr). C: FoxO3 gene expression in Dex or
EtOH-treated myotubes infected with shRNA
lentiviral particle against p300 or control scr.
Fold induction represents the ratio of Dex-
treated samples to EtOH-treated ones. Error
bar represents means 	 SE; n 
 3. *P 
0.05. D: FoxO3 protein expression in Dex or
EtOH-treated myotubes infected with shRNA
lentiviral particle against p300 or control scr.
One representative result was shown from 2
independent experiments. The intensity of
bands were measured using ImageJ. The bar
graph shows the average of 2 independent
experiments. Error bar represents means 	
SE. *P  0.05.
E581REGULATION OF FOXO3 GENE BY GLUCOCORTICOIDS
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00214.2015 • www.ajpendo.org
 by guest on August 5, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
-17648 +73506 +75896 +70172 -5014 578 +49809 +53118 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
Primer 
A 
B 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Fo
ld
 E
nr
ic
hm
en
t (
D
ex
/E
tO
H
) 
Primer 
* *
Region 1 Region 2 Region 3 
-17648 
-5014 
+578 
+4
98
09
 
+5
31
18
 +7
01
72
 
+7
35
06
 
+7
58
96
 
C 
0 
0.5 
1 
1.5 
2 
2.5 
Primer 7 Primer 14 
Fo
ld
 e
nr
ic
hm
en
t (
D
ex
/E
tO
H
) 
FoxO3 genoomic region 
sh-scr 
sh-p300 
D 
*
*
Fig. 6. Chromatin conformation capture (3C) identifies potential physical interaction between genomic regions near GBRs and transcription start site (TSS) of
FoxO3 gene. C2C12 myotubes were treated with 1 M Dex or control EtOH for 1 h. DNA was digested with Bgl II and re-ligated with DNA ligase
intermolecularly, and qPCR was used to detect the amount of ligated products obtained from individual primer set pairing region 1 (17,648, 5,014, 578),
region 2 (49,809, 53,118), and region 3 (70,172, 73,506, 75,896). The nucleotide position represents mid-point of each primer. A: schematic diagram
of Bgl II sites in regions 1, 2, and 3 of the FoxO3 gene. White boxes represent the two exons. B: PCR amplification results of primer set 1–14. The data represent
means 	 SE of fold enrichment (Dex- to EtOH-treated samples) from 7 independent experiments. A bacterial artificial clone (BAC, RP24-177H14) harboring
the entire FoxO3 genomic region was used as control for random chromatin interaction. The data shown here all have higher amount of ligated products in Dex-
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pairing 73,506 to 17,648 and 17,648 to 578, respectively. *P  0.05. C: Circos plot interprets the results from B and indicates relative crosslinking
frequencies observed between positions in regions 1, 2, and 3. D: 3C performed with C2C12 myotubes expressing scramble shRNA or p300 shRNA. Fold
enrichment was calculated by taking the ratio of Dex- to EtOH-treated cells from 2 independent experiments. *P  0.05.
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GBR is already exposed for GR binding. It could explain the
absence of chromatin structural change in the 17kbGBR. In
the mean time, increasing histone acetylation surrounding
GBRs would loosen the chromatin structure near GREs to
allow other transcription factors to associate with their respec-
tive binding sites to further assist transcriptional activation.
It is intriguing that these three GBRs respond to glucocor-
ticoid treatment differently to modify their chromatin structure.
Previous studies have shown that the nucleotide sequence of a
GRE plays a central role in modulating GR function (24, 45),
as distinct GRE sequences were shown to induce different
conformational change of GR (30). This is likely affecting the
ability of GR to associate with transcriptional coregulators and
other DNA-binding transcription factors (27, 45). We therefore
hypothesize that distinct sets of transcriptional coregulators
may be recruited to FoxO3 GBRs in a time-dependent fashion.
So far, p300 was the only transcriptional coregulator that we
found to be recruited to all three GBRs upon Dex treatment for
30 min. Dex-induced FoxO3 gene transcription appears to
require p300, as p300 reduction markedly decreased the ability
of Dex to stimulate FoxO3 gene expression. It is possible that
p300, a histone acetyltransferase, participates in the hyper-
acetylation of genomic regions at and/or surrounding GREs
shown in Fig. 3. To understand the differential effects of Dex
on the chromatin structure change, one would need to identify
transcription coregulators that are differentially recruited to
GBRs, possibly at distinct time points of Dex treatment, in
future studies.
Third, in 3C experiments, we found that 60-min Dex treat-
ment increases the interaction between genomic region down-
stream of 71kbGBR and the 17kbGBR and between the
17kbGBR and the genomic region around 578 bp. Based
on these results, we contemplated a model for FoxO3 genomic
configuration upon GR activation (Fig. 7). In this model, the
17kbGBR is drawn to the 578-bp genomic region upon
glucocorticoid treatment to be closer to the TSS. If we consider
these interactions in a three-dimensional geometry, the71kb-
GBR could also be close to the TSS through its communication
with the 17kbGBR (Fig. 7). Likely, there is no direct inter-
action between genomic regions around 73kb and 578 bp,
as we did not detect any ligated PCR product with respective
primers. Nonetheless, such spatial arrangements could still
play a role in transcription regulation (12, 31). There is no
available restriction site that allows us to study genomic
regions closer to TSS than 578 region. Nevertheless, we
speculate that 578 region may contain regulatory elements
required for maximal glucocorticoid response in FoxO3 gene
transcription.
It is likely that certain levels of DNA looping occur before
the Dex treatment, as we had positive qPCR results from 14
primer pairs in EtOH-treated C2C12 myotubes. These results
are not surprising, as DNA looping may be required to provide
basal transcription of FoxO3. Nuclear run-on first showed
Dex-induced FoxO3 gene transcription at 30-min time point,
whereas DNA looping was augmented after 1-h Dex treatment
in 3C analysis. This suggests that the basal level of DNA
looping is sufficient to support the initiation of FoxO3 tran-
scription by Dex. Enhanced DNA looping induced by Dex at
the 1-h time point may be required to sustain prolonged FoxO3
gene transcription. Alternatively, we cannot exclude the pos-
sibility that DNA looping is increased outside of tested
genomic regions by 30 min of Dex treatment. We did not
observe an increased interaction between the 45kbGBR and
genomic regions tested. However, it does not exclude the
possibility that the 45kbGBR is drawn to the TSS upon
glucocorticoid treatment at an earlier or later time point or the
possibility that the 45kbGBR may interact with genomic
regions outside the ones tested.
The induction of DNA looping by glucocorticoids has been
shown in other cases (11, 13, 17). However, the mechanism of
glucocorticoid-induced DNA looping is not clear. One DNA
binding protein that can induce DNA looping is CTCF (10, 26,
38, 44). Cohesin has been shown to act with CTCF to induce
DNA looping (5, 6). Based on CTCF ChIP sequencing results
from the University of California, Santa Cruz genome browser,
there are multiple CTCF binding sites in the FoxO3 genomic
region. It is unclear whether these CTCF binding sites play a
role in basal and Dex-induced DNA looping in FoxO3 genomic
region. In addition to CTCF, other transcription cofactors may
participate in DNA looping event in a glucocorticoid-depen-
dent manner. It has been shown that Mediators form a complex
with cohesin to participate in the induction of DNA looping
(18). SWI/SNF chromatin remodeling complex has also been
shown to induce chromatin looping (19). It is well established
that GR can recruit Mediator (2, 3) and SWI/SNF complexes
(16, 49). So far we were not able to detect the recruitment of
-17kb GBR +45kb GBR +71kb GBR 
-17kb GBR Ac 
+45kb GBR 
Ac Ac 
+71kb GBR 
Ac 
+1 
+500bp 
Ac 
Ac 
Ac Ac 
TSS 
TSS 
+1 
30 min 
1 h 
Fig. 7. Schematic model of glucocorticoid-induced
FoxO3 chromatin structural change. The chromatin
structure of the FoxO3 gene upon 30-min and 1-h Dex
treatment. The arrow points to the location of each
conserved GRE. The black ovals indicate packed
nucleosomes, while the white ovals represent nucleo-
somes that are loosened or disrupted. Ac indicates
hyperacetylated histones. Before Dex treatment there
are basal levels of DNA looping in FoxO3 gene. Dex
treatment for 1 h, however, induces DNA looping,
which in turn increases the interaction between
71kbGBR and 17kbGBR and between genomic
regions near 17kbGBR and TSS.
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components in Mediator and SWI/SNF to FoxO3 GBRs. How-
ever, p300 was recruited to all three GBRs. Recent studies
suggest that histone hyperacetylation induced by p300 contrib-
utes to DNA looping between locus control region and globin
gene promoter (20). Indeed, when we reduced p300 expression
in C2C12 myotubes, the ability of glucocorticoids to induce
DNA looping within FoxO3 gene was markedly reduced. It is
unclear how p300 exerts this effect; nonetheless, these exper-
iments established a role of p300 in this process.
Since the three GREs showed distinct regulatory character-
istics, it is likely that they serve different functions in the
activation of FoxO3 gene transcription. We speculate that
45kbGBR is involved in the initial step of transcriptional
activation, as chromatin structure surrounding45kbGBR was
loosened upon 30-min Dex treatment (Fig. 7). This initial step
may include the recruitment of proteins to initiate DNA loop-
ing, as we observed the interaction between 71kbGBR and
17kbGBR upon 1-h Dex treatment, at which time point the
chromatin structure surrounding 45kbGBR has returned to
the basal state. At this time point, chromatin structure sur-
rounding 71kbGBR has loosened up, which may in turn
recruit additional GR and/or other transcription factors and
interact with 17kbGBR to activate transcription (Fig. 7). To
test the role of each GRE, it would be necessary to delete or
mutate them individually and endogenously to examine the
effects on transcriptional activation process.
In summary, in this report we have shown that glucocorti-
coids employ a novel mechanism in regulating FoxO3 gene
transcription, where three GBRs, with a total of four GREs, are
involved in the transcriptional activation process. The interac-
tion between two GBRs and genomic region 578 bp down-
stream of TSS likely plays a role in Dex-induced FoxO3 gene
transcription. Further study of these transcriptional regulations
not only is important for understanding glucocorticoid action in
skeletal muscle but also provides a valuable model for eluci-
dating the complex mechanisms of GR-regulated gene tran-
scription.
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